These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9746788)

  • 21. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
    Bollard CM; Straathof KC; Huls MH; Leen A; Lacuesta K; Davis A; Gottschalk S; Brenner MK; Heslop HE; Rooney CM
    J Immunother; 2004; 27(4):317-27. PubMed ID: 15235393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Major histocompatibility complex (MHC)-I and MHC-II expression in Hodgkin's disease in relation to the presence of Epstein-Barr Virus (EBV).
    Tzardi M; Kouvidou C; Papakonstantinou E; Datseris G; Darivianaki K; Karidi E; Eliopoulos G; Delidis G; Rontogianni D; Kanavaros P
    Anticancer Res; 1996; 16(2):827-31. PubMed ID: 8687136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
    Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.
    Straathof KC; Leen AM; Buza EL; Taylor G; Huls MH; Heslop HE; Rooney CM; Bollard CM
    J Immunol; 2005 Sep; 175(6):4137-47. PubMed ID: 16148164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of human tumor-associated antigen RCAS1 in Reed-Sternberg cells in association with Epstein-Barr virus infection: a potential mechanism of immune evasion.
    Ohshima K; Muta K; Nakashima M; Haraoka S; Tutiya T; Suzumiya J; Kawasaki C; Watanabe T; Kikuchi M
    Int J Cancer; 2001 Jul; 93(1):91-6. PubMed ID: 11391627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of interleukin-6 expression in Hodgkin and Reed-Sternberg cells by Epstein-Barr virus.
    Herbst H; Samol J; Foss HD; Raff T; Niedobitek G
    J Pathol; 1997 Jul; 182(3):299-306. PubMed ID: 9349232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma.
    Diepstra A; Poppema S; Boot M; Visser L; Nolte IM; Niens M; Te Meerman GJ; van den Berg A
    Tissue Antigens; 2008 Mar; 71(3):219-26. PubMed ID: 18257895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
    Niedobitek G; Agathanggelou A; Rowe M; Jones EL; Jones DB; Turyaguma P; Oryema J; Wright DH; Young LS
    Blood; 1995 Jul; 86(2):659-65. PubMed ID: 7605996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease.
    Frisan T; Sjöberg J; Dolcetti R; Boiocchi M; De Re V; Carbone A; Brautbar C; Battat S; Biberfeld P; Eckman M
    Blood; 1995 Aug; 86(4):1493-501. PubMed ID: 7632957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of Epstein-Barr virus in the pathogenesis of Hodgkin's disease.
    Niedobitek G
    Ann Oncol; 1996; 7 Suppl 4():11-7. PubMed ID: 8836403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression.
    Li J; Zhang XS; Xie D; Deng HX; Gao YF; Chen QY; Huang WL; Masucci MG; Zeng YX
    Cancer Biol Ther; 2007 Dec; 6(12):1997-2004. PubMed ID: 18087217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-12 expression in human lymphomas and nonneoplastic lymphoid disorders.
    Schwaller J; Tobler A; Niklaus G; Hurwitz N; Hennig I; Fey MF; Borisch B
    Blood; 1995 Apr; 85(8):2182-8. PubMed ID: 7718889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human herpesvirus-6 (HHV-6) in Hodgkin's disease: cellular expression of viral antigens as compared to oncogenes met and fes, tumor suppressor gene product p53, and interleukins 2 and 6.
    Krueger GR; Guenther A; Knuefermann R; Kluppelberg U; Luka J; Pearson GR; Ablashi DV; Juecker M; Tesch H
    In Vivo; 1994; 8(4):501-16. PubMed ID: 7893977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
    Gavioli R; Vertuani S; Masucci MG
    Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease.
    Kohrt H; Johannsen A; Hoppe R; Horning SJ; Rosenberg SA; Advani R; Lee PP
    Oncol Res; 2009; 18(5-6):287-92. PubMed ID: 20225766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease.
    Robertson KD; Manns A; Swinnen LJ; Zong JC; Gulley ML; Ambinder RF
    Blood; 1996 Oct; 88(8):3129-36. PubMed ID: 8874213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease.
    Glavina-Durdov M; Jakic-Razumovic J; Capkun V; Murray P
    Br J Cancer; 2001 May; 84(9):1227-34. PubMed ID: 11336475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle.
    Vockerodt M; Wei W; Nagy E; Prouzova Z; Schrader A; Kube D; Rowe M; Woodman CB; Murray PG
    J Pathol; 2013 Aug; 230(4):399-409. PubMed ID: 23592216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting tumour cells with defects in the MHC Class I antigen processing pathway with CD8+ T cells specific for hydrophobic TAP- and Tapasin-independent peptides: the requirement for directed access into the ER.
    Aladin F; Lautscham G; Humphries E; Coulson J; Blake N
    Cancer Immunol Immunother; 2007 Aug; 56(8):1143-52. PubMed ID: 17143611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression.
    Kienzle N; Sculley TB; Poulsen L; Buck M; Cross S; Raab-Traub N; Khanna R
    J Virol; 1998 Aug; 72(8):6614-20. PubMed ID: 9658107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.